menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Poster Pearl: Examining Systemic Therapy for BPDCN While Also Treating or Prophylaxing CNS Involvement with IT Chemotherapy

ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post SurveySkip straight to the post survey if you have already participated in this activity
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A recent study sought to determine whether CNS treatment or prophylaxis combined with systemic tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) impacts patient prognosis and the efficacy of tagraxofusp. According to the results presented as a poster at the 2022 European Hematology Association Annual Congress, treatment with tagraxofusp and intrathecal chemotherapy was associated with promising efficacy in patients with CNS disease, with no unexpected safety events. Joining Dr. Charles Turck to share the key findings and how they may impact the way we approach treating patients with BPDCN is Dr. Justin Taylor, Assistant Professor of Hematology at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    A recent study sought to determine whether CNS treatment or prophylaxis combined with systemic tagraxofusp therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN) impacts patient prognosis and the efficacy of tagraxofusp. According to the results presented as a poster at the 2022 European Hematology Association Annual Congress, treatment with tagraxofusp and intrathecal chemotherapy was associated with promising efficacy in patients with CNS disease, with no unexpected safety events. Joining Dr. Charles Turck to share the key findings and how they may impact the way we approach treating patients with BPDCN is Dr. Justin Taylor, Assistant Professor of Hematology at the Sylvester Comprehensive Cancer Center of the University of Miami Miller School of Medicine.

Facebook Comments

Schedule19 Apr 2024